Catalent Company profile
Catalent Pharma is the US number one health products and solutions provider. The company specialises in biologics, pre-formulation and formulation and runs its own optoform technology. Catalent Pharma prides itself on 1,300 patents and 7,000 products currently in market. The company's operations stretch across Asia Pacific, Europe, Latin America, and North America, covering more than 100 global markets.
Since 2014, Catalent stocks have been traded on the New York Stock Exchange (NYSE) under the CTLT ticker. The company is featured in the Top 50 pharma and Top 50 biotech companies lists. As of May 2018, the Catalent market cap reached 5.348B.
Browse the latest Catalent share price data and tap into the pharma industry at Capital.com.
Latest shares articles
GBP/USD in focus ahead of FED and BOE meetings
Both the Federal Reserve and Bank of England will deliver their updated monetary policies this week, with GBP/USD likely to experience increased momentum.
22 hours ago
The markets expect FOMC to cut but outlook in 2025 is less certain
Markets expect a 25bp rate cut at the FOMC meeting on December 18, 2024, amid strong U.S. economic data. However, the outlook for 2025 remains uncertain as inflation and growth trends evolve.
12:56, 17 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
10:09, 13 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
12:58, 12 December 2024
Ratings and Reviews
Ratings and Reviews
